ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,567.19
1.06%
Dow Jones
39,375.87
0.17%
US Dollar vs MXN
18.0671
-0.13%
Brent Oil
85.845
-0.76%
Bitcoin
55,295.23
-0.99%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
Símbolo desconocido
Fecha:
Ordernar por:
FechaHoraFuenteTítuloSímboloCompañía
08/07/202401:10GlobeNewswire Inc.Mujtaba Khalid, Islamic finance thought leader, joins XTCC Advisory Team
08/07/202401:07GlobeNewswire Inc.OKX Wallet Now Integrated with The Beacon, an Action RPG
08/07/202401:00GlobeNewswire Inc.LEXIBOOK : RÉSULTATS ANNUELS 2023-24 CONFORMES AUX ATTENTES : CHIFFRE D’AFFAIRES ANNUEL À 58,6M€ (+14,4%). REX ET RN EN CROISSANCE RESPECTIVEMENT À +6,0M€ ET À +5,0M€ GRACE A UNE CONJONCTION EXCEPTIONNELLE DE FACTEURS POSITIFS.EU:ALLEXLexibook Linguistic Electronic System SA
08/07/202401:00GlobeNewswire Inc.Memo Therapeutics AG appoints Paul Carter as Chairperson
08/07/202401:00GlobeNewswire Inc.Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical DevelopmentNYSE:ADCTADC Therapeutics SA
08/07/202401:00Business WireSignum Surgical Granted FDA De Novo Clearance for BioHealx™
08/07/202401:00Business WireEpsilogen announces CTA approval for Phase Ib trial of MOv18 IgE in platinum-resistant ovarian cancer
08/07/202401:00GlobeNewswire Inc.Renforcement en Europe
08/07/202401:00GlobeNewswire Inc.Volta Finance Limited - Dividend DeclarationLSE:VTAVolta Finance Limited
08/07/202401:00GlobeNewswire Inc.EUR 200 million share buyback program beginsLSE:31QWAegon Nv
08/07/202401:00GlobeNewswire Inc.Evolution de la Gouvernance de la sociétéEU:OREGEOrege
08/07/202401:00GlobeNewswire Inc.LEXIBOOK: 2023-24 ANNUAL RESULTS IN LINE WITH EXPECTATIONS: ANNUAL SALES AT €58.6M (+14.4%). EBIT AND NET RESULT UP RESPECTIVELY TO +6.0M€ AND +5.0M€ THANKS TO AN EXCEPTIONAL CONJUNCTION OF POSITIVE FACTORS.EU:ALLEXLexibook Linguistic Electronic System SA
08/07/202401:00Business WireSpineGuard : Réalisation de l’augmentation de capital avec maintien du droit préférentiel de souscription pour un montant brut de 1,13 M€EU:ALSGDSpineguard
08/07/202401:00GlobeNewswire Inc.Strengthened presence in Europe
08/07/202401:00GlobeNewswire Inc.OKX to List XRADERS' XR Token on its Spot Market, Expanding Trading Options
08/07/202401:00GlobeNewswire Inc.Transaction in Own SharesTG:PANPaypoint PLC
08/07/202401:00GlobeNewswire Inc.Subsea7 share repurchasesTG:SOCSubsea 7 SA
08/07/202401:00PR Newswire (US)National Plants at Work Week 2024: Embrace Vitamin Plant for a Balanced Life
08/07/202401:00PR Newswire (US)Biotrend and Freepoint Eco-Systems Join Forces in Strategic Partnership to Create Value from Waste Plastics
08/07/202400:56GlobeNewswire Inc.AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19LSE:0Q77Ab Science Sa
08/07/202400:56GlobeNewswire Inc.AB Science annonce des résultats positifs de son étude de Phase 2 évaluant le masitinib dans la Covid-19EU:ABAb Science
08/07/202400:46Alliance NewsAlliance NewsLONDON MARKET EARLY CALL: Stocks called up; France political deadlock
08/07/202400:41PR Newswire (US)BioCity announces its endothelin receptor A selective antagonist SC0062 met the primary endpoint in IgA nephropathy in 2-SUCCEED trial: a randomized, double-blind, placebo-controlled Phase 2 trial
08/07/202400:32Alliance NewsAlliance NewsGET READY: Knights Group, ME Group, Unite Group at 0700 BST
08/07/202400:31Alliance NewsAlliance NewsAlliance News UK - start of day
08/07/202400:30GlobeNewswire Inc.BGHL (GBP): NAV(s)EU:BGHSBoussard and Gavaudan Holding
08/07/202400:30GlobeNewswire Inc.BGHL (EUR): NAV(s)LSE:BGHLBoussard & Gavaudan Holding Limited
08/07/202400:30GlobeNewswire Inc.Sampo plc’s share buybacks 5 July 2024
08/07/202400:28NEWSBTCDogecoin Price Recovery May Stall: Resistance Levels to WatchCOIN:BTCUSDBitcoin
08/07/202400:27CointelegraphWeekend Wrap: Germany moves $80M more BTC, Vitalik donates 100 ETH and moreCOIN:ETHUSDEthereum

Su Consulta Reciente

USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
JPM
JP Morgan Chase
NYSE
DIS
Walt Disney
AMEX
SPY
SPDR S&P 500
AMEX
XLV
Health Care Select Sector
FX
EURUSD
Euro vs US Dollar
FX
USDMXN
US Dollar vs MXN
NYSE
CVX
Chevron
SPI
SP500
S&P 500
NASDAQ
GOOGL
Alphabet
COIN
SOLUSD
Solana
AMEX
XLF
Financial Select Sector
NASDAQ
NVDA
NVIDIA
CCOM
US30
US 30
USOTC
ADDYY
Adidas (QX)
NYSE
NKE
Nike
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados